Biocon wins European Commission nod for breast cancer biosimilar
In short
Biocon has received European Commission approval for its breast cancer biosimilar under a tailored clinical pathway.
BusinessLine says this is Biocon’s fifth oncology biosimilar approved in Europe and the US, adding to its cancer drug portfolio.
What the reporting says
Biocon has received European Commission approval for its breast cancer biosimilar under a tailored clinical pathway. BusinessLine’s summary says this is the company’s fifth oncology biosimilar approved in Europe and the US. The clearance expands Biocon’s oncology biosimilar portfolio and adds to its regulated-market approvals.
Why it matters
Biocon has won European Commission approval for its breast cancer biosimilar through a tailored clinical pathway. The company’s summary says this is its fifth oncology biosimilar approved in Europe and the US. The decision matters to Biocon because it expands its biosimilar portfolio in regulated markets and strengthens its oncology presence.